Previous Article | Next Article ![]()
Infection and Immunity, June 2000, p. 3297-3304, Vol. 68, No. 6
Department of Bacteriology and Medical
Mycology1 and Department of Veterinary
Medicine,3 Istituto Superiore di
Sanità, Rome, and Department of Pharmacological
Sciences and Experimental Medicine, University of Camerino,
Camerino,2 Italy
Received 13 December 1999/Returned for modification 27 January
2000/Accepted 17 March 2000
Humoral (antibody [Ab]) and cellular Candida-specific
immune responses in the vaginas of pseudoestrus rats were investigated during three successive infections by Candida albicans.
After the first, protective infection, Abs against mannan and aspartyl proteinase antigens were present in the vaginal fluid, and their titers
clearly increased during the two subsequent, rapidly healing infections. In all animals, about 65 and 10% of vaginal lymphocytes (VL) were CD3+ (T cells) and CD3 Vaginal candidiasis is a widespread,
common disease affecting a substantial proportion of childbearing-age
women (27), but the pathogenesis of this frequent clinical
problem remains elusive. Clinical studies on recurrent vulvovaginal
candidiasis as well as several investigations with estrogen-dependent
murine models of vaginal candidiasis (9, 10) led to the
suggestion that cell-mediated immunity (CMI) plays a critical role in
anticandidal protection at the vaginal level. However, the specific
nature of the cellular immunoprotective factor(s) has not been
identified. Somewhat in contrast with the above suggestion, evidence
from experimental settings points to antibodies (Abs) against specific virulence factors of the fungus playing a critical role in protection. In fact, anticandidal protection can be efficiently conferred by
actively induced or passively administered antimannan and
anti-secretory aspartyl proteinase (Sap) Abs, inclusive of specific
monoclonal Abs in both rat and mouse models of vaginal candidiasis
(3, 4, 14, 15, 20). Nonetheless, this contrast may be
apparent only as CMI exerts a critical regulatory role in anticandidal responses (26), as also witnessed by the lack of protection induced by active Candida antigen immunization in
congenitally athymic, nude rats (3). Thus, the study of
cellular immunity at the vaginal level remains a key point for an
understanding of local host defense, whatever the ultimate
effector mechanism. Accordingly, we have attempted to identify
the T-cell populations in the vaginal mucosa of naive and
Candida-infected rats. Antigen-induced expansion and
activation of lymphocyte populations, and cytokines in the vaginal
fluid of infected, nonimmune and immune rats were also sought for to
obtain possible insights into the immunoregulatory mechanisms operating
at the vaginal level during, and possibly acting against,
Candida infection.
Microorganisms and growth conditions.
The yeast used
throughout this study was Candida albicans SA-40, originally
isolated from the vaginal secretion of women with acute vaginitis
(4). For the experimental infection (see below), a stock
strain from Sabouraud-dextrose agar (Difco, Laboratories, Detroit,
Mich.) was grown in YEPD medium (yeast extract, 1%; neopeptone, 2%;
dextrose, 2%) for 24 h at 28°C under mild shaking, then
harvested by centrifugation (3,500 × g), washed, and
suspended to the required number in saline solution.
Animals.
Oophorectomized female Wistar rats (80 to 100 g; Charles River Breeding Laboratories, Calco, Italy) were used
throughout the study. Animal maintenance, estrogen treatment, and
general design of both the primary infection and rechallenges were as
described elsewhere (3, 4).
Experimental rat vaginitis.
The experimental infection was
carried out in oophorectomized rats essentially as described elsewhere
(4) except that a greater C. albicans inoculum
(108 rather than 107 cells) in 0.1 ml of saline
solution was used. Briefly, all rats were maintained under pseudoestrus
by subcutaneous administration of estradiol benzoate (Benzatrone;
Samil, Rome, Italy). Six days after the first estradiol dose, the
animals were inoculated intravaginally with the fungal cells, the
number of which in the vaginal fluid was monitored by culturing 1-µl
samples (taken from each animal by a calibrated plastic loop
[Disponoic; PBI, Milan, Italy]) on Sabouraud agar containing
chloramphenicol (50 µg/ml), as previously described (3,
4). A rat was considered infected when at least 1 CFU was present
in the vaginal sample (i.e., a count of ELISA to detect Abs against C. albicans constituents
in vaginal fluids.
The presence of Abs directed against mannan
antigens or Sap was assayed in the vaginal washes by a previously
described enzyme-linked immunosorbent assay (ELISA) (4).
Briefly, 200 µl of a mannan extract (>95% polysaccharide) solution
(5 µg/ml in 0.2 M sodium carbonate) was used as coating antigen for
the detection of antimannan Ab and was dispensed into the wells of a
polystyrene microtitration plate which was kept overnight at 4°C.
After three washes with Tween 20-PBS buffer, 1:2 dilutions of
supernatants of the vaginal fluids were distributed in triplicate
wells, and the plates were incubated for 1 h at room temperature.
Each well was washed again with Tween 20-PBS buffer, and predetermined
optimal dilutions of alkaline phosphatase-conjugated sheep anti-rat
immunoglobulin G (IgG), IgM, or IgA (obtained from Serotec Ltd.,
Kidlington, Oxford, United Kingdom) were added. Bound alkaline
phosphatase was detected by the addition of a solution of
p-nitrophenyl phosphate in diethanolamine buffer and the
plates were read at A405 with an automated
microreader (Labsystem Multiscan; Multiskan, Helsinki, Finland) blanked
against air. For anti-Sap Ab detection, the same ELISA was used, except
that a highly purified, non-mannan-containing Sap preparation was used
as the coating antigen (4). The enzyme preparation was
kindly provided by P. A. Sullivan (Palmerston North, New Zealand).
A vaginal fluid was considered positive for a determined Ab when the
optical density (OD) was greater than two times the value of the well
coated with the same antigen and incubated with the Ab-free vaginal
fluid of an uninfected rat.
Detection of cytokines in vaginal fluids.
Vaginal fluids
were taken from rats at different times during the infection, pooled
and centrifuged as described above, and assayed for the presence of
cytokines such as interleukin 2 (IL-2), IL-4, IL-5, and IL-12 by a
quantitative sandwich enzyme immunoassay technique (Quantikine; R-D
Systems, Minneapolis, Minn.). Gamma interferon (IFN-
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Local Anticandidal Immune Responses in a Rat Model of Vaginal
Infection by and Protection against Candida
albicans
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
CD5+ (B cells), respectively. Two-thirds of the
CD3+ T cells expressed the
/
and one-third expressed
the
/
T-cell receptor (TCR). This proportion slightly fluctuated
during the three rounds of C. albicans infection, but no
significant differences between infected and noninfected rats were
found. More relevant were the changes in the
CD4+/CD8+ T-cell ratio, particularly for cells
bearing the CD25 (interleukin-2 receptor
) marker. In fact, a
progressively increased number of both CD4+
/
TCR and
CD4+ CD25+ VL was observed after the second and
third Candida challenges, reversing the high initial
CD8+ cell number of controls (estrogenized but uninfected
rats). The CD3
CD5+ cells also almost doubled
from the first to the third infection. Analysis of the cytokines
secreted in the vaginal fluid of Candida-infected rats
showed high levels of interleukin 12 (IL-12) during the first infection, followed by progressively increasing amounts of
IL-2 and gamma interferon during the subsequent infections. No IL-4 or
IL-5 was ever detected. During the third infection, VL with in vitro
proliferative activity in response to an immunodominant mannoprotein antigen of C. albicans were present in the
vaginal tissue. No response to this antigen by mitogen-responsive
blood, lymph node, and spleen cells was found. In summary, the presence of protective Ab and T helper type 1 cytokines in the vaginal fluids,
the in vitro proliferation of vaginal lymphocytes in response to
Candida antigenic stimulation, and the increased number of activated CD4+ cells and some special B lymphocytes after
C. albicans challenge constitute good evidence for
induction of locally expressed Candida-specific Ab and
cellular responses which are potentially involved in anticandidal protection at the vaginal level.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
103 CFU/ml). Some
other vaginal samples were also stained by a periodic acid-Schiff-van
Gieson method for microscopic examination. This infection was repeated
a second and a third time, after resolution of each preceding infection
by an equal challenge with 108 C. albicans cells
and under identical estrogen treatment (see also Results). Samples of
vaginal fluids (vaginal washes) were taken at regular intervals from
each animal after the intravaginal challenge with yeast cells. The rat
vaginal cavity was washed by gentle injection and subsequent aspiration
of phosphate-buffered saline (PBS; 0.5 ml). The collected fluids were
pooled for each experimental group; the resultant 2.5 to 3 ml was
centrifuged for 15 min at 3,500 × g in a refrigerated
Biofuge, and the supernatant was assayed for vaginal Abs or cytokines
as described below.
) was detected
by ELISA (rat IFN-
; CYTOSCREEN; Biosource International, Camarillo,
Calif.).
, and IL-12, respectively. Before testing, each cytokine
standard was spiked with normal rat vaginal fluid to assay for possible
interferences. No such interferences on the standard curves of each
cytokine assay were detected.
Collection of VL.
The vagina was aseptically removed from
each sacrificed rat; the vaginal tissue was cut longitudinally and
minced with a sterile scalpel in complete medium consisting of RPMI
1640 supplemented with penicillin (100 U/ml), streptomycin (100 mg/ml),
L-glutamine (2 mM), sodium pyruvate (2 mM),
2-mercaptoethanol (5 × 10
5 M), and 5%
heat-inactivated fetal calf serum, all from Life Technology (Paisley,
Scotland, United Kingdom), with 25 mM HEPES buffer. Minced tissues were
digested in complete medium with sterile 0.25% collagenase D
(Boehringer, Mannheim, Germany), following incubation in a shaker at
37°C for 30 min. Before, during, and immediately after the incubation
period, samples were mixed in a stomacher homogenizer (Lab Blender 400 PBI). After digestion, tissues and cells were filtered through a
sterile gauze mesh, washed with RPMI 1640 medium, and centrifuged three
times (200, 800 and 1,800 × g for 15 min each time).
Finally, the cells were collected from the supernatant, resuspended in
Hanks buffered salt solution, counted, and assessed for viability by
trypan blue dye exclusion. About 80% of these cells were vaginal
lymphocytes (VL), as judged by morphology in Giemsa-stained smears.
Approximately 2 × 105 viable VL were collected from
each vagina.
Other cell preparation. Spleens were aseptically removed from sacrificed rats. Spleen cells were teased, and cellular debris was removed. The cell suspensions were counted and diluted at an appropriate concentration (106/ml) in RPMI 1640 medium (Flow Laboratories, Irvine, United Kingdom) containing 10% heat-inactivated fetal calf serum (Flow), 2 mM L-glutamine (Gibco Laboratories, Grand Island, N.Y.), penicillin (100 IU/ml; Gibco), streptomycin (100 µg/ml; Gibco), and 20 mM HEPES (Gibco) (complete medium) for proliferation assays.
Heparinated venous peripheral blood was withdrawn by cardiac puncture from CO2-anesthetized rats. Peripheral blood mononuclear cells (PBMC) were isolated by centrifugation on Ficoll-Hypaque (Lymphoprep; Nicamed, Oslo, Norway) gradients, washed twice, counted, and finally resuspended at the appropriate concentration in complete medium for proliferation assays. Mesenteric, inguinal lymph nodes were collected, and single-cell suspensions were prepared with sterile mesh screen. Lymph node cells (LNC) were treated with Tris-ammonium chloride to lyse erythrocytes, washed twice with Hanks balanced salt solution (Gibco), counted, and resuspended at the appropriate concentration in complete medium for proliferation assays. PBMC, LNC, and spleen cell viability was assessed by trypan blue exclusion and was routinely greater than 95%. The proliferation assay with all of these cells was performed as described for VL.Mitogen and antigen stimulants. Phytohemagglutinin (PHA) was from Difco Laboratories. Mannoprotein (MP-F2) was extracted from the yeast form of C. albicans BP serotype A and prepared for use as an antigenic stimulant as described elsewhere (13, 28, 29).
Vaginal cell proliferation. VL were suspended in complete RPMI medium supplemented with the antimycotic meparthricine (amphothericin methylester; 50 µg/ml; kindly provided by V. Strippoli, University of Rome "La Sapienza," Rome, Italy), dispensed into tissue culture-treated plastic 96-well, round-bottomed microtiter plates (Costar, Cambridge, Mass.) at a final concentration of 105 cells/0.1 ml, and cultured in a total volume of 200 µl of culture medium with PHA (1 µg/µl) for 72 h, or MP-F2 (100, 10, or 1 µg/ml) for 6 days, at 37°C under 5% CO2 humified atmosphere. Cell proliferation was evaluated by thymidine incorporation (0.5 µCi of [3H]thymidine {[3H]TdR}; specific activity, 6.7 Ci/mmol; New England Nuclear, Boston, Mass.) during the last 6 h of the culture. Incorporation of [3H]TdR was measured by standard liquid scintillation counting after harvesting the cells with a Skatron (Oslo, Norway) apparatus. All cultures were run in quadruplicate.
Abs.
Phycoerythrin (PE)- and fluorescein isothiocyanate
(FITC)-conjugated Ab specific for rat CD3 (pan-T), CD4, CD5 (T and a
subset of B cells in Wistar rats) (18, 19), CD8a, CD25 (IL-2
receptor
[IL-2 R
]),
/
T-cell receptor (TCR), and
/
TCR were from Pharmingen Corp. (San Diego, Calif.). Mouse
FITC-conjugated Abs (Becton Dickinson, Mountain View, Calif.) were used
as negative controls.
Immunofluorescence and flow cytometric analysis. Standard methodology was used for direct single and double immunofluorescence of VL. Briefly, 2 × 105 VL from C. albicans-infected and control rats were resuspended in complete medium, pelleted, and then incubated with the appropriate Ab or negative control for 30 min at 4°C. After three washes with cold PBS, the VL were analyzed for relative fluorescence intensity. For double immunofluorescence, PE- or FITC-conjugated Ab was incubated for an additional 30 min on ice with the respective FITC- or PE-conjugated Ab and similarly washed with cold PBS. The percentage of positive-stained cells determined over 10,000 events was analyzed on FACScan cytofluorimeter (Becton Dickinson). Fluorescence intensity was expressed in arbitrary units on a logarithmic scale. Cells incubated with mouse FITC-IgG1, rat PE-IgG2a, and FITC-isotype control Ab were used to determine the background fluorescence. Compensation for each fluorochrome was determined by parallel single-color analysis of cells labeled with one of the fluorochrome-conjugated Abs.
Histology. After rats were sacrificed, the vagina was removed and immediately fixed in 10% (vol/vol) neutral buffered formalin. After dehydration in a graded ethanol series and clearing with xylene, the material was embedded in paraffin, and 8-µm-thick sections were stained with hematoxylin-eosin for observation under the light microscope.
| |
RESULTS |
|---|
|
|
|---|
Outcome of, and Ab production during, three successive rounds of
vaginal infections by C. albicans.
We reassessed the
susceptibility of oophorectomized, estradiol-treated rats to vaginal
infection and reinfection by C. albicans as well as
antimannan and anti-Sap Ab production under the conditions selected for
this study, which included an intravaginal inoculum of C. albicans cells higher than that routinely used in this model (3, 4) (see below). Figure 1
shows the kinetics of first, second, and third challenges of C. albicans (each with 188 cells and up to day 21 postinfection). After the first intravaginal challenge on day 0, > 105 Candida CFU/ml of vaginal fluid could be
found during the first 3 to 4 days postinfection, and then the
Candida vaginal burden slowly declined, approaching the
lowest detectable value by our method (103 CFU/ml) on week
4 postinfection. Vaginal smears taken at intervals during infection
demonstrated sustained hyphal growth starting 1 day postinfection and
extending through day 14. If rechallenged with C. albicans 1 week after resolution of the primary infection (day 35), the reinfected
animals cleared the second infection much more rapidly than the first
one, as the limit of 103 CFU/ml was approached at the end
of the first week of infection and no Candida CFU could be
detected by the end of the second week. At this time, a new rechallenge
(third infection) again resulted into a very rapid clearance of the
infecting fungus, similarly to the kinetics of clearance measured in
the second infection (Fig. 1).
|
|
Cytokines in vaginal fluids.
Because of the critical
immunoregulatory role of cytokines in the induction and persistence
of specific cellular and Ab responses (26), the vaginal
fluids from rats taken at intervals during the three infection rounds
were evaluated for the presence of cytokines representative of
both T helper type 1 (Th1) (IFN-
and IL-2) and Th2 (IL-4 and
IL-5) patterns. IL-12, a Th1-driving cytokine, was also searched
for. For both the first and second infections, appreciable amounts of
type 1 cytokines were found in the vaginal fluids. This was
particularly observed during the first 2 to 3 days (in the case of
IFN-
[Fig. 3A]) and rather constantly during the whole infection round for IL-2 (Fig. 3B). A
remarkable increase in their level was detected soon after the third
challenge, with peaks of IFN-
(around 1,500 pg/ml) and IL-2 (around
550 pg/ml) on days 7 and 3, respectively. While the intravaginal level
of IFN-
then declined to undetectable values, IL-2 remained
detectable, though with quantitative fluctuations, throughout the
infectious period, in both the first and second infectious cycles (Fig.
3A and B). In contrast, much higher levels of IL-12 were measured
during the first, immunizing intravaginal infection than in the two
subsequent ones, although it remained detectable during each infection
round (Fig. 3C).
|
and
IL-12 (never >50 pg/ml) were found in the vaginal fluid of some of
these rats.
Vaginal cell populations.
The results above, showing
remarkable, infection-associated modulations of cytokines produced by T
cells and present in the vaginal fluid, prompted us to evaluate the
hypothesis that intravaginal lymphocyte populations could also show
modulations during the three subsequent infections. We particularly
focused on vaginal T cells because congenital athymia negated induction
of protection following the first immunizing Candida
infection (4) and also because T cells were previously
characterized as dominant lymphocyte populations in a mouse model of
vaginal candidiasis (12). To this end, VL isolated from
collagenase-digested vaginal tissue on day 7 after each infection
round, as well as on the corresponding day of estrogen treatment in
uninfected rats, were labeled with FITC-conjugated anti-CD3 antibody
and analyzed by flow cytometry. In control rats, CD3+ VL
represented about two-thirds of the total viable cells harvested from
rat vagina. The CD3
VL were not extensively
characterized. However, about 25% of them expressed the CD5 marker,
which is present on certain B-lymphocyte subsets in mice and in Wistar
rats (18, 19). Background fluorescence, as determined by
cellular staining with mouse PE-conjugated IgG1 and FITC-conjugated
IgG2B, was negligible and had no effects on VL staining (data not
shown). Following dual labeling with FITC- or PE-conjugated anti-CD3
antibodies coupled with PE-conjugated anti-
/
or FITC-conjugated
anti-
/
TCR Ab, about two-thirds of these CD3+ VL
expressed the
/
TCR and the remaining third expressed the
/
receptor. Although fluctuating during the three infection rounds, this
proportion differed only slightly at the third infection cycle from
that measured in the control, estrogenized animals (Table
1).
|
/
(or anti-
/
) TCR Ab together
with either anti-CD4 or anti-CD8 Ab. As shown in Table 1, the CD4/CD8
VL ratio was inverted compared to that of the blood (where the ratio
fluctuates around a value of 3:1), as CD8+ cells were more
numerous than the CD4+ cells, especially in estrogenized
rats after the first infection. However, the proportion of
CD4+ T cells showed a clear rising during the other two
infection rounds, nearly regaining the ratio (almost 1:1) measured in
the control (uninfected and nonestrogenized) rats. Table 1 also shows that the above changes affected almost exclusively the CD4+
and CD8+ cells bearing the
/
TCR, as the number of
/
TCR cells remained substantially unchanged. Finally, dual
labeling with anti-CD4 (CD8) Abs followed by anti-CD25 Ab showed a very
substantial increase of both CD4 and CD8 cells bearing the CD25
activation marker during the three infection rounds. After the third
infection, this marker appeared to be expressed by the large majority
of the VL (79 and 65% of CD4+ and CD8+ cells,
respectively) starting from less than 10% positivity of both cell
types in noninfected, estrogenized rats. Of interest is also the
increase in the proportion of the CD3
CD5+
cells, which were more than 50% of all CD3
VL on day 7 of the third infection (not shown).
Histology.
Sections of the vaginal tissue were examined during
each infection round for evidence of cell infiltration and other
histological changes. No or very few mononuclear cells within the
mucosal tissue were detected during the first round of infection either
in the vaginal epithelium or in the fiber-rich subepithelial space
(Fig. 4a and b). In contrast, starting
from the end of the second to the whole third cycle of infection,
numerous infiltrating inflammatory (prevalently mononuclear) cells were
observed in the subepithelial lamina propria and also infiltrating
within the epithelium of the mucosal tissue (Fig. 4c and d). In
definite vaginal subepithelial areas, clusters of mononuclear cells
were quite prominent (Fig. 4e).
|
VL proliferation.
The data reported above, showing remarkable
expansion of CD4+
/
TCR lymphocytes harvested from
the vaginas of estrogenized rats during the three infections rounds,
also prompted us to examine whether Candida-specific
lymphocytes were present among the expanded and activated VL
populations. To this end, VL from animals on day 7 of each infection
round were cultured and stimulated in vitro with the polyclonal
stimulants PHA and concanavalin A, along with a mannoprotein antigen
fraction of Candida (MP-F2) which proved to be an
immunodominant T-cell antigen in humans and able to promptly detect CMI
responses in Candida-immunized mice (21, 29).
For comparison, lymphocytes from spleens, lymph nodes, and blood of the
same rats were also cultured and stimulated in vitro with mitogen or
MP-F2. Mononuclear cell cultures from rats taken during the first and
second infection rounds, while promptly responding to PHA or con-A, did
not proliferate in response to the Candida antigen.
Conversely, vaginal but not blood, lymph node, and spleen lymphocytes
from rats taken after the third infection also responded, in a
dose-dependent manner, to stimulation with MP-F2 antigen (Fig.
5).
|
| |
DISCUSSION |
|---|
|
|
|---|
By extending previous observations by ourselves and others (3, 4, 8), we have demonstrated here that a spontaneously healing, primary Candida infection of rat vagina constitutes a potent inducer of a persistent immunoprotection against repeated challenges with high intravaginal Candida burdens. Protection was associated with the presence of antimannan and anti-Sap Abs, the levels of which were markedly boosted by the repeated challenges, particularly during the first week of the third infection. These Abs were previously shown to confer passive protection in Candida-infected, nonimmunized rats, a protection that could also be conferred by intravaginal administration of monoclonal Abs (IgG and IgM) against mannoside and peptide epitopes of mannan and Sap, respectively (4). Together with other recent data obtained by us (24) and by Han et al. (14, 15), the findings reported here constitute strong evidence that the persistent immunity resulting from the healing of a primary vaginal infection by Candida is eventually mediated by Abs of a definite specificity and probably isotype.
While highlighting the importance of Abs for anticandidal protection, previous studies also suggested a critical role of T cells in the induction of immunity at the vaginal level, as nude (congenitally athymic) rats were unable to mount a protective immunity after healing of the primary infection or active immunization with the protective Candida antigens (3, 4). These latter observations are totally consistent with the impressive, though indirect, clinical evidence regarding the susceptibility of T-cell-deficient subjects to mucosal candidiasis (17, 25) as well as with the findings from studies of normal and genetically modified mice (2, 9, 22, 26).
For these reasons, we addressed here the composition of vaginal T-cell
populations, their activation state, and the amount of T-cell-derived
cytokines in the vaginal fluid of rats during subsequent challenges
following the primary, immunoprotective infection. Also on the basis of
previous data by others (10-12), we assumed that if T cells
have a role in vaginal immunity and this immunity is so
compartmentalized, an obvious (and necessary) consequence is that
changes, even only functional, in the regulatory and effector
mechanisms of local anticandidal immunity should be manifested on
induction of protection. The cellular milieu of the vagina does indeed
contain all kinds of effector and accessory cells, such as
antigen-presenting cells, and both
/
and
/
CD4+
and CD8+ T cells, which are competent for induction and
expression of specific adaptive immunity.
Four observations made here give strong support to the above
assumption. First, we found that induction of pseudoestrus (a condition for effective vaginal candidiasis in the rat model) substantially influenced the CD4+/CD8+ VL
ratio, which fell to 0.25 from about 1 for the control (uninfected and
nonestrogenized) rats. Noteworthy, a progressive shift in the ratio of
CD4+ to CD8+
/
vaginal T cells in favor
of the CD4+ components occurred with the progressive
infection rounds, regaining the value (approximately 1) found in the
control rats. Second, most of the CD4+ and CD8+
rat VL increasingly expressed the IL-2 R
marker on the subsequent infections. Remarkably, no numerical change was induced in the CD4+/CD8+ T cells bearing the
/
T-cell
receptor. Third, there were progressively increasing amounts of Th1
cytokines in the vaginal fluid of infected rats along with the
progression of the infectious cycles. This was particularly evident
with IL-2, of which there was a sustained production during the third
infection, a finding which is also consistent with CD25 expression and
suggests a pronounced T-cell activation in the vagina. Of interest here
is that remarkable amounts of the Th1 cytokine pattern-driving IL-12
were also detected during the primary, immunizing infection, while not
even traces of the Th2-type cytokines IL-4 and IL-5 were detected. This
suggests the induction of a definitely dominant Th1 cytokine pattern in our infection model. Fourth, and probably of greater functional importance, the VL population from the third infection round was shown
to contain Candida-specific lymphocytes, capable of
intensely proliferating upon recognition of an immunodominant and
protective Candida mannoprotein antigen (21, 29).
Interestingly, neither lymphocytes from peripheral blood nor
those from spleen or lymph nodes responded to this antigen, though
they were fully responsive to polyclonal stimulant.
These results provide the first evidence that a
Candida-specific cellular response wholly restricted to
vaginal level is induced and expressed during a rodent vaginal
infection by C. albicans and is associated to a
protective anti-Candida state in the vagina. The
cytofluorimetric analysis suggests that this immune response may be due
to the expansion and activation of vaginal T lymphocytes of
CD4+
/
TCR phenotype. Since neither blood nor lymph
node or spleen T cells proliferated upon stimulation by
Candida antigen, it would seem unlikely that the vaginal
lymphocytes are Candida-sensitized T cells infiltrating the
vagina from the periphery. However, it is still possible that the
Candida-specific "vaginal" lymphocytes do indeed come
from the periphery, being attracted by the potent, local antigenic
stimulus constituted by the second and third infectious burdens, and
that the number of residual specific T cells in the blood or lymph node
is too low for lymphoproliferation in vitro. Our histological pictures
suggest a pronounced degree of inflammation occurring at the vaginal
level during the second and third Candida infections, with
prevalently mononuclear cell components. There are also reports that
estrogen treatment favors the transmigration of lymphocytes into the
mucosa of the genital tract, although this seems to occur more to the
uterus than to the vagina (25). However, the whole picture
could be more consistent with in situ activation and multiplication of
intra- and subepithelial vaginal lymphocyte populations.
Since the focus of these experiments was on T-cell composition and
activation, no detailed analysis of the CD3
cells, which
constituted about one-third of the viable vaginal cells in control
rats, was performed. Nonetheless, the presence of the CD5 marker in a
consistent proportion of these cells suggests that B lymphocytes are
also present in the vagina. Besides the T cells, the CD5 determinant
does indeed characterize a subpopulation of estrogen-sensitive
lymphocytes in Wistar rats (19). Interestingly, CD3
CD5+ cells also significantly increased
their relative proportion from the first to the third infection
round (9.6 to 20.8% of the vaginal cells). Since other B cells of
Wistar rats do not express the CD5 marker (18), the
proportion of vaginal B lymphocytes could be still higher.
Determination of the true role of CD5+ or CD5
B lymphocytes in the expression of Candida-reactive VL
properties such as lymphoproliferation and antibody production awaits
more in-depth investigations. These might be particularly revealing inasmuch as the CD5+ murine lymphocytes have been shown to
have a restricted VH usage and have been thought to exert a
primary role as first-line Ab producers against microbial cell surface
antigens (18, 19). These investigations are in progress in
our laboratories.
While evidence similar to our own has been obtained in other models of experimental vaginal infection (e.g., with Chlamydia trachomatis [23]), our findings would appear to be somewhat distinct from those obtained by Fidel and collaborators in a murine vaginal infection by Candida. In this model, no numerical changes or activation of specific vaginal T-cell populations during both primary and secondary infections, and no influence of estrogen on these populations, were found (11, 12). In addition, no VL proliferation induced by Candida antigens was shown.
Another important difference is that Candida-specific T cells in the blood were induced by vaginal infections in the murine model, without apparent infiltration of these cells into the vaginal tissue (11).
Nonetheless, the above differences may be related to differential
features of the two experimental models. Although both require estrogens for Candida infection, the rat model also requires
oophorectomy; more important, the initial composition of vaginal T
cells appears to be substantially different, as CD8+
/
TCR cells are at a level equal to or greater than that of CD4+ cells in the rat vagina, whereas many more cells of
the latter phenotype are present in mouse vagina (12). In
addition, an influence of estrogen treatment on the
CD8+/CD4+ ratio is clear in our model.
Interestingly, this ratio seems to be close to that found in the vagina
of normal women (5), suggesting that the rat model could, in
theory, better reflect the human clinical situation. Finally, VL
proliferation in response to Candida antigen stimulation
was, in our model, detected only during the third infection round, in
animals which were evidently hyperimmunized by the repeated
Candida intravaginal challenges. The data reported by Fidel
et al. (12) are apparently restricted to the second infection.
The absence of Th2 cytokines coupled with the marked elevation of Th1
cytokine (IFN-
and IL-2) levels between the second and the third
challenges was remarkable. Importantly, it was clearly preceded by the
production of high levels of IL-12, a Th1 pattern-driving cytokine,
during the primary, immunizing infection. All of these findings
demonstrate the induction of a definitely dominant type 1 cytokine
pattern in our experimental setting, probably related to the maturation
and expansion of a major category of Th1 cytokine-producing cells such
as the CD4+
/
TCR, but also to the marked cellular
activation, as demonstrated by the high percentage of CD25 expression
noticed in both CD4+ and CD8+ cells. These
latter cells are also good producers of IFN-
and have been reported
to express anticandidal activity when activated by IL-2, of which there
was high intravaginal production during the third infection
(1). Interestingly, the highest intravaginal levels of both
IFN-
and IL-2 persisted after most of the fungal burden was
eliminated from the rat vagina. Of interest is also that the highest
IFN-
level in the vaginal fluid was measured on day 7 of the third
infection, when the highest Ab levels were also detected (cf.
Fig. 2A and B and 3A), suggesting a possible relationship between the
two events. Both IFN-
and IL-2 indeed play a role also in Ab
(especially of some isotype) maturation. Besides confirming the
importance of a Th1 induction pattern for anticandidal protection
(7, 10, 26) as well as suggesting its probable role in
protective Ab responses, our findings suggest that the protection at
vaginal level is related to the persistence (memory) of a specific,
locally restricted immune activated state. Studies of the antigenic
specificity and TCR repertoire of vaginal T-cell clones could help us
draw a definite conclusion in this matter.
From all of the available evidence, it seems fair to conclude that vaginal T cells undergo remarkable quantitative and qualitative changes during repeated vaginal infections by C. albicans in rats. Candida-specific cellular immunity is achievable and demonstrable on repeated vaginal challenges with the fungus, and this immunity is vaginally restricted and associated with a dominant Th1 cytokine pattern. Although its exact role in anticandidal protection at the vaginal level and its possible relationship with the generation of protective Abs (3, 4) remain to be defined, the presence of Candida-specific VL paves the way for directly addressing the protective potential of these cells by adoptive transfer experiments.
| |
ACKNOWLEDGMENTS |
|---|
We are grateful to Angela Santoni for critical reading of the manuscript and providing useful suggestions. The careful assistance of Francesca Girolamo and Anna Botzios in preparation of the manuscript is gratefully acknowledged. Antonietta Girolamo helped in the preparation of vaginal cells.
This work was supported in part by the National AIDS Research Program, under I.S.S. contract 50 C/B.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Bacteriology and Medical Mycology, Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161 Rome, Italy. Phone: 39-06-49387113. Fax: 39-06-49387112. E-mail: cassone{at}iss.it.
Editor: T. R. Kozel
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Beno, D., and H. L. Mathews. 1993. Quantitative measurements of lymphocyte-mediated growth inhibition of Candida albicans. J. Immunol. Methods 164:155-164[CrossRef][Medline]. |
| 2. |
Cantorna, M. T., and E. Balish.
1991.
Role of CD4+ lymphocytes in resistance to mucosal candidiasis.
Infect. Immun.
59:2447-2455 |
| 3. | Cassone, A., M. Boccanera, D. Adriani, G. Santoni, and F. De Bernardis. 1995. Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection. Infect. Immun. 63:2619-2625[Abstract]. |
| 4. | De Bernardis, F., M. Boccanera, D. Adriani, E. Spreghini, G. Santoni, and A. Cassone. 1997. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect. Immun. 65:3399-3405[Abstract]. |
| 5. | Elitsur, Y., S. Jackman, C. Neace, S. Keerthy, X. Liu, J. Dosescu, and J. A. Moshier. 1998. Human vaginal mucosa immune system: characterization and function. Gen. Diagn. Pathol. 143:271-277[Medline]. |
| 6. |
Fidel, P. L., Jr.,
M. E. Lynch, and J. D. Sobel.
1993.
Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis.
Infect. Immun.
61:1990-1995 |
| 7. |
Fidel, P. L., Jr.,
M. E. Lynch, and J. D. Sobel.
1993.
Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis.
Infect. Immun.
61:4202-4207 |
| 8. | Fidel, P. L., Jr., M. E. Lynch, D. H. Conaway, L. Tait, and J. D. Sobel. 1995. Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity. Infect. Immun. 63:547-553[Abstract]. |
| 9. | Fidel, P. L., Jr., and J. D. Sobel. 1996. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin. Microbiol. Rev. 9:335-348[Abstract]. |
| 10. | Fidel, P. L., Jr., W. Luo, J. Chabain, N. A. Wolf, and E. Van Buren. 1997. Use of cellular depletion analysis to examine circulation of immune effector function between the vagina and the periphery. Infect. Immun. 65:3939-3943[Abstract]. |
| 11. | Fidel, P. L., Jr., K. A. Ginsburg, J. L. Cutright, N. A. Wall, D. Lennan, K. Dunlap, and J. D. Sobel. 1997. Vagina-associated immunity in women with recurrent vulvovaginal candidiasis: evidence for vaginal Th-1 type responses following intravaginal challenge with Candida antigen. J. Infect. Dis. 176:728-739[Medline]. |
| 12. |
Fidel, P. L., Jr.,
W. Luo,
C. Steele,
J. Chaban,
M. Baker, and F. Wormley, Jr.
1999.
Analysis of vaginal cell populations during experimental vaginal candidiasis.
Infect. Immun.
67:3135-3140 |
| 13. | Gomez, M. J., A. Torosantucci, S. Arancia, B. Maras, L. Parisi, and A. Cassone. 1996. Purification and biochemical characterization of a 65-kilodalton mannoprotein (MP65), a main target of anti-Candida cell-mediated immune responses in humans. Infect. Immun. 64:2577-2584[Abstract]. |
| 14. | Han, Y., and J. E. Cutler. 1995. Antibody response that protects against disseminated candidiasis. Infect. Immun. 63:2714-2719[Abstract]. |
| 15. |
Han, Y.,
R. P. Morrison, and J. E. Cutler.
1998.
A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection.
Infect. Immun.
66:5771-5776 |
| 16. | Kearsy, J. A., and A. W. Stadnyk. 1996. Isolation and characterization of highly purified rat intestinal intraaepithelial lymphocytes. J. Immunol. Methods 194:35-48[CrossRef][Medline]. |
| 17. | Klein, R. S., C. A. Harris, C. Butkus Small, B. Moll, M. Lesser, and G. H. Friendland. 1984. Oral candidiasis in high risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N. Engl. J. Med. 311:354-357[Abstract]. |
| 18. | Kroese, F. G. M., E. C. Butcher, P. A. Lalor, A. M. Stall, and L. A. Herzenberg. 1990. The rat B cell system: the anatomical localization of flow cytometry-defined B cell subpopulations. Eur. J. Immunol. 20:1527-1534[Medline]. |
| 19. | Martin, A., A. Vicente, M. Torroba, C. Moreno, E. Jimènez, and A. G. Zapata. 1996. Increased numbers of CD5+ B cells in the thymus of estradiol benzoate-treated rats. Thymus 24:111-127[Medline]. |
| 20. | Mathur, S., G. Virella, J. Koistinen, E. O. Horger, A. Mahvi, and H. H. Fudenberg. 1992. Humoral immunity in vaginal candidiasis. Infect. Immun. 15:287-294. |
| 21. |
Mencacci, A.,
A. Torosantucci,
R. Spaccapelo,
L. Romani,
F. Bistoni, and A. Cassone.
1994.
A mannoprotein constituent of Candida albicans that elicits different level of delayed-type hypersensitivity, cytochine production, and anticandidal protection in mice.
Infect. Immun.
62:5353-5360 |
| 22. | Mulero-Marchese, R., K. J. Blank, and T. G. Sieck. 1988. Genetic basis for protection against experimental vaginal candidiasis by peripheral immunization. J. Infect. Dis. 178:227-234. |
| 23. |
Perry, L.,
L. K. Feilzer, and H. D. Caldwell.
1997.
Immunity to Chlamidia trachomatis is mediated by T helper 1 cells through IFN- -dependent and -independent pathways.
J. Immunol.
158:3344-3351[Abstract].
|
| 24. | Polonelli, L., F. De Bernardis, S. Conti, M. Boccanera, M. Gerloni, G. Morace, W. Magliani, C. Chezzi, and A. Cassone. 1994. Idiotypic intravaginal vaccination to protect against Candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J. Immunol. 152:3175-3182[Abstract]. |
| 25. | Prabhala, R. H., and C. R. Wira. 1995. Influence of estrus cycle and estradiol on mitogenic responses of splenic T and B lymphocytes., p. 379-381. In J. Mestecky, et al. (ed.), Advances in mucosal immunology. Plenum Press, New York, N.Y. |
| 26. | Romani, L. 1997. The T cell response against fungal infections. Curr. Opin. Immunol. 9:484-490[CrossRef][Medline]. |
| 27. | Sobel, J. D. 1992. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin. Infect. Dis. 14:148-153. |
| 28. | Torosantucci, A., C. Bromuro, M. J. Gomez, C. M. Ausiello, F. Urbani, and A. Cassone. 1993. Identification of a 65-kDa mannoprotein as a main target of human cell-mediated immune response to Candida albicans. J. Infect. Dis. 168:427-435[Medline]. |
| 29. |
Torosantucci, A.,
C. Palma,
M. Boccanera,
C. M. Ausiello,
G. C. Spagnoli, and A. Cassone.
1990.
Lymphoproliferative and cytotoxic responses of human peripheral blood mononuclear cells to mannoprotein constituents of Candida albicans.
J. Gen. Microbiol.
136:2155-2163 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»